Completed PHASE3 INTERVENTIONAL 3-arm NCT00200343

Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C

A 24-week Multicenter Double-blind Control Trial With Ursodeoxycholic Acid in Patients With Chronic Hepatitis C

Sponsor: Tanabe Pharma Corporation

Interventions Ursodeoxycholic acid 150mg / day Ursodeoxycholic acid 600mg / day Ursodeoxycholic acid 900mg / day

Updated 10 times since 2017 Last updated: Dec 15, 2025 Started: Jul 31, 2002 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Chronic Hepatitis C and is currently completed. Tanabe Pharma Corporation leads this study, which shows 10 recorded versions since 2002 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE3
Jan 2026 — Feb 2026 [monthly]

Completed PHASE3
Sep 2025 — Jan 2026 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tanabe Pharma Corporation

Data source: Tanabe Pharma Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hongo, Bunkyo-ku, Tokyo, Japan